Last 25 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 46.17 | 29.34 | 23.54 | 58.33 | — | 37.90 | — | — | — | 1413.31 | 64.09 | 368.75 | 50.89 | 45.76 | 117.45 | 61.69 | 48.13 | 77.53 | 53.50 | 93.21 | 125.78 |
| — | -22.6% | — | — | — | -97.3% | — | — | — | +2988.3% | -45.4% | +497.8% | +5.7% | -41.0% | +119.5% | -33.8% | -61.7% | -59.6% | -58.8% | — | — | |
| P/B Ratio | 1.14 | 1.20 | 1.04 | 0.93 | 0.89 | 1.55 | 1.44 | 1.65 | 2.81 | 3.78 | 3.47 | 2.82 | 1.45 | 1.32 | 1.66 | 1.62 | 1.71 | 1.70 | 1.47 | 1.66 | 2.22 |
| — | -23.0% | -27.8% | -43.9% | -68.2% | -59.0% | -58.4% | -41.5% | +93.4% | +186.5% | +109.1% | +73.5% | -14.8% | -22.2% | +12.7% | -2.4% | -23.1% | -28.2% | +126.3% | — | — | |
| P/FCF | — | — | 19.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.7% | -336.5% | 100.0% | 100.0% | — | 100.0% | — | — | — | 100.0% | 100.0% | 57.5% | 78.4% | 80.1% | -1311.9% | -674.7% | 100.0% | -657.7% | -495.6% | -540.9% | -591.2% |
| — | -436.5% | — | — | — | 0.0% | — | — | — | +24.8% | +107.6% | +108.5% | -21.6% | +112.2% | -164.7% | -24.7% | +116.9% | -5.2% | +43.9% | -33.0% | — | |
| Operating Margin | -1576.7% | -336.5% | -308.7% | -916.5% | — | -352.5% | — | — | — | -8164.5% | -155.4% | -1610.3% | -655.7% | -628.2% | -1962.9% | -990.3% | -642.0% | -994.0% | -729.9% | -852.2% | -834.8% |
| — | +4.5% | — | — | — | +95.7% | — | — | — | -1199.6% | +92.1% | -62.6% | -2.1% | +36.8% | -168.9% | -16.2% | +23.1% | -5.7% | +43.7% | -41.8% | — | |
| Net Margin | -1136.3% | -232.2% | -214.0% | -652.6% | — | -243.1% | — | — | — | -6391.6% | -67.0% | -1178.9% | -477.8% | -459.6% | -1656.4% | -852.5% | -564.7% | -920.9% | -714.1% | -843.9% | -830.2% |
| — | +4.5% | — | — | — | +96.2% | — | — | — | -1290.7% | +96.0% | -38.3% | +15.4% | +50.1% | -132.0% | -1.0% | +32.0% | +0.9% | +44.5% | -40.4% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -11.5% | -2.3% | -2.4% | -2.6% | -3.3% | -2.5% | -3.4% | -2.3% | -2.4% | -4.3% | -0.9% | -3.0% | -3.4% | -3.6% | -5.7% | -5.5% | -4.9% | -4.9% | -4.8% | -3.7% | -3.6% |
| — | +5.1% | +30.5% | -11.1% | -37.2% | +42.1% | -272.6% | +21.7% | +29.0% | -19.7% | +84.2% | +46.6% | +31.1% | +27.8% | -18.8% | -48.8% | -36.4% | -74.9% | -43.1% | — | — | |
| ROA | -11.0% | -2.2% | -2.2% | -2.4% | -3.1% | -2.4% | -3.3% | -2.2% | -2.3% | -4.0% | -0.9% | -2.8% | -3.1% | -3.2% | -5.0% | -4.9% | -4.3% | -4.4% | -4.5% | -3.6% | -3.5% |
| — | +8.4% | +33.6% | -7.5% | -36.6% | +41.6% | -276.5% | +19.4% | +24.9% | -27.4% | +82.9% | +43.3% | +29.4% | +27.6% | -12.6% | -35.9% | -24.8% | -60.5% | -69.1% | +30.9% | +65.9% | |
| ROIC | -15.3% | -2.6% | -2.6% | -2.8% | -3.4% | -2.8% | -3.5% | -3.3% | -3.4% | -4.1% | -1.8% | -3.7% | -3.4% | -3.7% | -5.2% | -5.1% | -4.7% | -4.5% | -4.2% | -3.2% | -3.0% |
| — | +6.4% | +26.3% | +15.9% | +1.3% | +32.1% | -92.6% | +10.3% | -0.2% | -11.2% | +64.9% | +26.8% | +26.8% | +18.8% | -22.7% | -57.5% | -54.6% | -29.8% | +79.3% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.04 | 0.04 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.00 | 0.00 |
| — | -3.7% | +1.0% | +2.6% | +2.8% | -35.0% | -38.1% | -39.4% | -68.4% | -49.9% | -57.0% | -55.1% | -9.7% | -1.8% | +24.0% | +18982.1% | +14786.0% | +11546.3% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 39.04 | 17.69 | 16.35 | 17.01 | 39.04 | 35.86 | 47.03 | 58.47 | 59.21 | 38.80 | 57.34 | 62.09 | 26.80 | 24.55 | 17.28 | 19.95 | 20.14 | 21.08 | 27.56 | 29.14 | 29.46 |
| — | -50.7% | -65.2% | -70.9% | -34.1% | -7.6% | -18.0% | -5.8% | +120.9% | +58.1% | +231.9% | +211.3% | +33.1% | +16.4% | -37.3% | -31.5% | -31.6% | -32.5% | -36.0% | +181.3% | +483.5% | |
| Quick Ratio | 39.04 | 17.69 | 16.35 | 17.01 | 39.04 | 35.86 | 47.03 | 58.47 | 59.21 | 38.80 | 57.34 | 62.09 | 26.80 | 24.55 | 17.28 | 19.95 | 20.14 | 21.08 | 27.56 | 29.14 | 29.46 |
| — | -50.7% | -65.2% | -70.9% | -34.1% | -7.6% | -18.0% | -5.8% | +120.9% | +58.1% | +231.9% | +211.3% | +33.1% | +16.4% | -37.3% | -31.5% | -31.6% | -32.5% | -36.0% | +181.3% | +483.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JANX stock.
Janux Therapeutics, Inc.'s current P/E is -11.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Janux Therapeutics, Inc.'s current operating margin is -1576.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Janux Therapeutics, Inc.'s business trajectory between earnings reports.